372 related articles for article (PubMed ID: 36499358)
1. Emerging Potential Mechanism and Therapeutic Target of Ferroptosis in PDAC: A Promising Future.
Li C; Yin X; Liu Z; Wang J
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499358
[TBL] [Abstract][Full Text] [Related]
2. Exploiting the ferroaddiction of pancreatic cancer cells using Fe-doped nanoparticles.
Lomphithak T; Sae-Fung A; Sprio S; Tampieri A; Jitkaew S; Fadeel B
Nanomedicine; 2024 Jan; 55():102714. PubMed ID: 38738528
[TBL] [Abstract][Full Text] [Related]
3. Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer.
Singh K; Pruski M; Bland R; Younes M; Guha S; Thosani N; Maitra A; Cash BD; McAllister F; Logsdon CD; Chang JT; Bailey-Lundberg JM
Lab Invest; 2021 Feb; 101(2):177-192. PubMed ID: 33009500
[TBL] [Abstract][Full Text] [Related]
4. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).
Zhang J; Darman L; Hassan MS; Von Holzen U; Awasthi N
Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800636
[TBL] [Abstract][Full Text] [Related]
5. Pan-KRAS inhibitors suppress proliferation through feedback regulation in pancreatic ductal adenocarcinoma.
Wang CX; Wang TT; Zhang KD; Li MY; Shen QC; Lu SY; Zhang J
Acta Pharmacol Sin; 2022 Oct; 43(10):2696-2708. PubMed ID: 35352018
[TBL] [Abstract][Full Text] [Related]
6. Ferroptosis: New Strategies and Ideas for the Treatment of Pancreatic Ductal Adenocarcinoma.
Yang C; Dong Q; Bao H; Ge Y; Xu Z; Li J; Jiang X; Xu Y; Zhong X
Front Biosci (Landmark Ed); 2024 Jan; 29(1):45. PubMed ID: 38287825
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
8. Cell death in pancreatic cancer: from pathogenesis to therapy.
Chen X; Zeh HJ; Kang R; Kroemer G; Tang D
Nat Rev Gastroenterol Hepatol; 2021 Nov; 18(11):804-823. PubMed ID: 34331036
[TBL] [Abstract][Full Text] [Related]
9. The Art of War: Ferroptosis and Pancreatic Cancer.
Liu J; Kang R; Tang D
Front Pharmacol; 2021; 12():773909. PubMed ID: 34955844
[TBL] [Abstract][Full Text] [Related]
10. Targeting KRAS in pancreatic cancer.
Stickler S; Rath B; Hamilton G
Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
[TBL] [Abstract][Full Text] [Related]
11. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation.
Nolan-Stevaux O; Lau J; Truitt ML; Chu GC; Hebrok M; Fernández-Zapico ME; Hanahan D
Genes Dev; 2009 Jan; 23(1):24-36. PubMed ID: 19136624
[TBL] [Abstract][Full Text] [Related]
12. Small-Molecule MMRi62 Induces Ferroptosis and Inhibits Metastasis in Pancreatic Cancer via Degradation of Ferritin Heavy Chain and Mutant p53.
Li J; Lama R; Galster SL; Inigo JR; Wu J; Chandra D; Chemler SR; Wang X
Mol Cancer Ther; 2022 Apr; 21(4):535-545. PubMed ID: 35131878
[TBL] [Abstract][Full Text] [Related]
13. Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma.
Rajpurohit T; Bhattacharya S
Curr Mol Pharmacol; 2022; 15(7):904-928. PubMed ID: 35088684
[TBL] [Abstract][Full Text] [Related]
14. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
Xie F; Li C; Zhang X; Peng W; Wen T
Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
[TBL] [Abstract][Full Text] [Related]
15. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma.
Li JT; Yin M; Wang D; Wang J; Lei MZ; Zhang Y; Liu Y; Zhang L; Zou SW; Hu LP; Zhang ZG; Wang YP; Wen WY; Lu HJ; Chen ZJ; Su D; Lei QY
Nat Cell Biol; 2020 Feb; 22(2):167-174. PubMed ID: 32029896
[TBL] [Abstract][Full Text] [Related]
16. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy.
Gurreri E; Genovese G; Perelli L; Agostini A; Piro G; Carbone C; Tortora G
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298264
[TBL] [Abstract][Full Text] [Related]
17. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
[TBL] [Abstract][Full Text] [Related]
18. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Krake S; Radefeldt M; Al-Ali R; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457227
[TBL] [Abstract][Full Text] [Related]
20. Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer.
Sun Y; Peng W; He W; Luo M; Chang G; Shen J; Zhao X; Hu Y
J Exp Clin Cancer Res; 2018 Jul; 37(1):166. PubMed ID: 30041673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
